There are 2949 resources available
LBA32 - Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Presenter: Robert Coleman
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
807O - Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)
Presenter: Kohei Omatsu
Session: Proffered Paper - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1O - A study of cancer dissemination from metastatic intermediates of hypermethylated colorectal patients reveals a new mode of collective migration
Presenter: Emmanuel Dornier
Session: Proffered Paper - Basic Science
Resources:
Abstract
Slides
Webcast
1977O - Functional inactivation of E-cadherin drives EMT-less metastasis
Presenter: Saverio Alberti
Session: Proffered Paper - Basic Science
Resources:
Abstract
Slides
Webcast
2O - Growth differentiation factor 15 (GDF-15) neutralization reverses cancer cachexia, restores physical performance and mitigates emesis associated with platinum-based chemotherapy
Presenter: Zhidan Wu
Session: Proffered Paper - Basic Science
Resources:
Abstract
Slides
Webcast
3O - Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer
Presenter: Anna Diana
Session: Proffered Paper - Basic Science
Resources:
Abstract
Slides
Webcast
700O - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
Presenter: Maxime Meylan
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Presenter: Zeynep Zengin
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Presenter: Sumanta Pal
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast
LBA25 - Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Presenter: Yann Vano
Session: Proffered Paper - GU, non prostate 2
Resources:
Abstract
Slides
Webcast